Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Int. j. morphol ; 39(2)abr. 2021. 659^c666
Article in English | LILACS | ID: biblio-1385365

ABSTRACT

SUMMARY: The aim of this study was to determine the relationship of autophagy-enhancing rapamycin (RAPA) and autophagy- inhibitor 3-methyladenine (3-MA) with Nitric oxide synthases (NOS) in Cisplatin (CIS)-induced neurotoxicity in rats. Rats were divided into 4 groups (n=10): Control was applied saline, CIS (a single dose of 8mg/kg intraperitoneal (i.p.) on 7th day of experiment), RAPA+CIS (2 mg/kg/i.p. RAPA per day and 8 mg/kg/i.p. CIS on 7th day), 3-MA+CIS (15 mg/kg/i.p. 3-MA per day and 8 mg/kg/i.p. CIS on 7th day). Rats were sacrificed under anesthesia. Brain tissues were evaluated histopathologically. eNOS, Inos, nNOS and MAP 2 immunostaining were performed to determine the expression levels of these proteins among groups. Superoxide dismutase (SOD), Catalase (CAT), Malondialdehyde (MDA) and Interleukin IL-6 levels in brain tissue and serum nitric oxide (NO) level were measured by ELISA assay. In histopathological evaluation, neurodegeneration was seen in the CIS group. There was an increase in eNOS, iNOS and nNOS immunostaining in CIS group. While MAP2 immunostaining of the CIS group decreased. There was a decrease in SOD and CAT levels of brain tissue in CIS group. However, there was an increase in MDA, IL-6 and NO levels of brain tissue in CIS group. We found that antioxidant capacity increase while, inflammation and nitric oxide levels decreased in the RAPA-treated group. 3-MA does not have a significant effect. We suggest that CIS-induced neurotoxicity is more effective than Rapa 3-MA and may also be linked to NOS enzymes.


RESUMEN: El objetivo de este estudio fue determinar la relación de la rapamicina potenciadora de la autofagia (RAPA) y el inhibidor de la autofagia 3-metiladenina (3-MA) con óxido nítrico sintasas (NOS) en la neurotoxicidad inducida por cisplatino (CIS) en ratas. Las ratas se dividieron en 4 grupos (n = 10): grupo control se aplicó solución salina, CIS (una dosis única de 8 mg / kg intraperitoneal (ip) el día 7 del experimento), RAPA + CIS (2 mg / kg / ipRAPA por día y 8 mg / kg / ip CIS el día 7), 3-MA + CIS (15 mg / kg / ip 3-MA por día y 8 mg / kg / ip CIS el día 7). Las ratas se sacrificaron bajo anestesia y los tejidos cerebrales fueron analizados histopatológicamente. Se realizaron inmunotinciones con eNOS, Inos, nNOS y MAP 2 para determinar los niveles de expre- sión de estas proteínas entre los grupos. Se midieron los niveles de superóxido dismutasa (SOD), catalasa (CAT), malondialdehído (MDA) e interleucina IL-6 en el tejido cerebral y el nivel de óxido nítrico (NO) en suero mediante ensayo ELISA. En la evaluación histopatológica, se observó neurodegeneración en el grupo CIS. Hubo un aumento en la inmunotinción de eNOS, iNOS y nNOS en el grupo CIS. Mientras que la inmunotinción de MAP2 del grupo CIS disminuyó. Hubo una disminución en los niveles de SOD y CAT del tejido cerebral en el grupo CIS, sin embargo, hubo un aumento en los niveles de MDA, IL-6 y NO en el tejido cerebral en el grupo CIS. Observamos que la capacidad antioxidante aumentó, mientras que la inflamación y los niveles de óxido nítrico disminuyeron en el grupo tratado con RAPA. 3-MA no tiene un efecto significativo. Sugerimos que la neurotoxicidad inducida por CIS es más eficaz que Rapa 3-MA y también puede estar relacio- nada con las enzimas NOS.


Subject(s)
Animals , Male , Rats , Adenine/analogs & derivatives , Cisplatin/toxicity , Nitric Oxide Synthase/drug effects , Sirolimus/pharmacology , Neurotoxicity Syndromes , Superoxide Dismutase , Enzyme-Linked Immunosorbent Assay , Immunohistochemistry , Adenine/pharmacology , Catalase , Interleukin-6 , Rats, Wistar , Malondialdehyde , Antineoplastic Agents/toxicity
2.
Braz. j. med. biol. res ; 53(3): e8761, 2020. tab, graf
Article in English | LILACS | ID: biblio-1089339

ABSTRACT

Nitric oxide (NO) inhibition by high-dose NG-nitro-L-arginine methyl ester (L-NAME) is associated with several detrimental effects on the cardiovascular system. However, low-dose L-NAME increases NO synthesis, which in turn induces physiological cardiovascular benefits, probably by activating a protective negative feedback mechanism. Aerobic exercise, likewise, improves several cardiovascular functions in healthy hearts, but its effects are not known when chronically associated with low-dose L-NAME. Thus, we tested whether the association between low-dose L-NAME administration and chronic aerobic exercise promotes beneficial effects to the cardiovascular system, evaluating the cardiac remodeling process. Male Wistar rats were randomly assigned to control (C), L-NAME (L), chronic aerobic exercise (Ex), and chronic aerobic exercise associated to L-NAME (ExL). Aerobic training was performed with progressive intensity for 12 weeks; L-NAME (1.5 mg·kg-1·day-1) was administered by orogastric gavage. Low-dose L-NAME alone did not change systolic blood pressure (SBP), but ExL significantly increased SBP at week 8 with normalization after 12 weeks. Furthermore, ExL promoted the elevation of left ventricle (LV) end-diastolic pressure without the presence of cardiac hypertrophy and fibrosis. Time to 50% shortening and relaxation were reduced in ExL, suggesting a cardiomyocyte contractile improvement. In addition, the time to 50% Ca2+ peak was increased without alterations in Ca2+ amplitude and time to 50% Ca2+ decay. In conclusion, the association of chronic aerobic exercise and low-dose L-NAME prevented cardiac pathological remodeling and induced cardiomyocyte contractile function improvement; however, it did not alter myocyte affinity and sensitivity to intracellular Ca2+ handling.


Subject(s)
Animals , Male , Physical Conditioning, Animal/physiology , Calcium/analysis , Nitric Oxide Synthase/drug effects , NG-Nitroarginine Methyl Ester/pharmacology , Enzyme Inhibitors/pharmacology , Myocardial Contraction/drug effects , Body Weight/physiology , Rats, Wistar , Ventricular Pressure/drug effects , Nitric Oxide Synthase/metabolism , NG-Nitroarginine Methyl Ester/administration & dosage , Models, Animal , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/physiology , Enzyme Inhibitors/administration & dosage , Adiposity , Hemodynamics , Motor Activity/physiology , Myocardium/pathology
3.
Rev. chil. cardiol ; 35(1): 41-48, 2016. ilus, graf
Article in Spanish | LILACS | ID: lil-782641

ABSTRACT

El infarto del miocardio es una de las principales causas de muerte a nivel mundial y se produce a consecuencia de procesos de isquemia-reperfusión (IR). El daño miocárdico generado por IR puede ser atenuado a través del pre-condicionamiento isquémico (PI) temprano, mediado por la vía RISK o PI tardío, que se asocia a una respuesta genómica en la que se activan proteínas como óxido nítrico sintasa inducible (iNOS). Las vías de señalización que median el PI también pueden ser activadas farmacológicamente. Dexmedetomi-dina (Dex) es un agonista alfa2-adrenérgico, que se ha descrito como un potente agente cardioprotector frente a IR. Recientemente, nuestro grupo describió que Dex requiere el endotelio y la activación de la vía óxido nítrico sintasa endotelial (eNOS)-óxido nítrico (NO) para pre-condicionar el miocardio. Sin embargo, no existen estudios que muestren la posible participación de iNOS en la protección conferida por Dex. La presente adenda tiene por objetivo evaluar si Dex activa iNOS en el corazón y en cardiomiocitos. Para esto, corazones de rata adulta fueron estimulados con Dex 10 nM y se observó que el fármaco aumentó la producción de NO medida por cuantificación de nitritos, mas no estimuló la activación de iNOS medida por Western blot. Además, Dex tampoco indujo el aumento de mRNA de iNOS en cardiomiocitos adultos. Por lo tanto, Dex genera NO independiente a iNOS durante su efecto pre-condicionante agudo. Sin embargo, se requieren más estudios que clarifiquen su papel en una posible protección a largo plazo frente a IR generada por Dex.


Myocardial infarction is one of the leading causes of death worldwide and is generated as a consequence of ischemia-reperfusion (IR). Myocardial damage inflicted by IR can be attenuate by early ische-mic pre-conditioning (IP), which is mediated by the RISK pathway or late IP, which is associated to a genomic response involving the activation of proteins such as inducible nitric oxide synthase (iNOS). The signaling pathways mediating IP can also be pharmacologically activated. Dexmedetomidine (Dex) is an alpha2-adrenergic receptor agonist, which has been described as a strong cardio protective agent against IR. Recently, our group reported that Dex requires the endothelium and the activation of the endothelial nitric oxide synthase (eNOS)-ni-tric oxide (NO) pathway to precondition the myocardium. However, there are no studies showing the involvement of iNOS in the protection elicited by Dex. The aim of this Addendum is to evaluate if Dex activates iNOS in the heart and cardiomyocytes. To test this, adult rat hearts were stimulated with Dex 10 nM and we observed that NO production measured by quantification of nitrites was increased, but Dex did not activate iNOS measured by Western blot. Moreover, Dex did not induce an increase in the mRNA levels of iNOS in adult cardiomyocytes. Therefore, Dex generates NO independent of iNOS during its early pre-conditioning effect. Nevertheless, more studies are required to clarify its role in a possible long term protection against IR generated by Dex.


Subject(s)
Animals , Rats , Reperfusion Injury/prevention & control , Nitric Oxide Synthase/drug effects , Ischemic Preconditioning, Myocardial/methods , Dexmedetomidine/administration & dosage , Adrenergic alpha-2 Receptor Agonists/administration & dosage , Cardiotonic Agents/administration & dosage , Blotting, Western , Rats, Sprague-Dawley , Disease Models, Animal , Real-Time Polymerase Chain Reaction
4.
Acta cir. bras ; 30(5): 345-352, 05/2015. tab, graf
Article in English | LILACS | ID: lil-747028

ABSTRACT

PURPOSE: To evaluated the effects of L-arginine (a NO donor) and L-NAME (Nw-nitro-L-arginine methyl ester - a NOS inhibitor) on ischemia-reperfusion in rat livers. METHODS: One hundred fifty two male Wistar rats were divided into four groups: control (simulated surgery); hepatic IR; pretreatment with L-arginine plus hepatic IR; and L-NAME plus hepatic IR. The hepatocellular damage was evaluated at the first, third and seventh days after the procedures through the alanine-aminotransferase (ALT) and aspartate-aminotransaminase (AST) levels, as well as histopathological features: vascular congestion (VC); steatosis (STE); necrosis (NEC); and inflammatory infiltration (INF). The mortality rate was also evaluated. RESULTS: The pretreatment with L-NAME significantly worsened the AST levels after hepatic IR (p<0.05) at first day and L-arginine demonstrated an attenuating effect on ALT levels at seventh day (p<0.05). Furthermore, the administration of L-arginine was able to reduce the VC and STE in the seventh day after hepatic IR (p<0.05). The analysis of the mortality rates did not demonstrate any difference between the groups. Nevertheless, there was not effect of L-arginine and L-NAME on the mortality of the animals. CONCLUSION: L-arginine/NO pathway has a role in the hepatic IR because the pretreatment with L-arginine partially had attenuated the hepatocellular damage induced by hepatic IR in rats. .


Subject(s)
Animals , Male , Arginine/therapeutic use , Enzyme Inhibitors/therapeutic use , Liver/blood supply , Liver/drug effects , NG-Nitroarginine Methyl Ester/therapeutic use , Reperfusion Injury/prevention & control , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Disease Models, Animal , Liver/pathology , Necrosis , Nitric Oxide Synthase/drug effects , Nitric Oxide Synthase/metabolism , Nitric Oxide/metabolism , Random Allocation , Rats, Wistar , Reference Values , Reproducibility of Results , Time Factors , Treatment Outcome
5.
Braz. j. med. biol. res ; 45(11): 1066-1073, Nov. 2012. ilus, tab
Article in English | LILACS | ID: lil-650568

ABSTRACT

The amino acid arginine (Arg) is a recognized secretagogue of growth hormone (GH), and has been shown to induce GH gene expression. Arg is the natural precursor of nitric oxide (NO), which is known to mediate many of the effects of Arg, such as GH secretion. Arg was also shown to increase calcium influx in pituitary cells, which might contribute to its effects on GH secretion. Although the mechanisms involved in the effects of Arg on GH secretion are well established, little is known about them regarding the control of GH gene expression. We investigated whether the NO pathway and/or calcium are involved in the effects of Arg on GH gene expression in rat isolated pituitaries. To this end, pituitaries from approximately 170 male Wistar rats (~250 g) were removed, divided into two halves, pooled (three hemi-pituitaries) and incubated or not with Arg, as well as with different pharmacological agents. Arg (71 mM), the NO donor sodium nitroprusside (SNP, 1 and 0.1 mM) and a cyclic guanosine monophosphate (cGMP) analogue (8-Br-cGMP, 1 mM) increased GH mRNA expression 60 min later. The NO acceptor hemoglobin (0.3 µM) blunted the effect of SNP, and the combined treatment with Arg and L-NAME (a NO synthase (NOS) inhibitor, 55 mM) abolished the stimulatory effect of Arg on GH gene expression. The calcium channel inhibitor nifedipine (3 µM) also abolished Arg-induced GH gene expression. The present study shows that Arg directly induces GH gene expression in hemi-pituitaries isolated from rats, excluding interference from somatostatinergic neurons, which are supposed to be inhibited by Arg. Moreover, the data demonstrate that the NOS/NO signaling pathway and calcium mediate the Arg effects on GH gene expression.


Subject(s)
Animals , Male , Rats , Arginine/pharmacology , Gene Expression Regulation/drug effects , Growth Hormone/genetics , Pituitary Gland/drug effects , Dose-Response Relationship, Drug , Growth Hormone/metabolism , Nitric Oxide Synthase/drug effects , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase/metabolism , Nitric Oxide/genetics , Nitric Oxide/metabolism , Pituitary Gland/metabolism , Rats, Wistar , Signal Transduction
6.
Braz. j. med. biol. res ; 45(2): 163-171, Feb. 2012. ilus, tab
Article in English | LILACS | ID: lil-614574

ABSTRACT

The objective of this study was to observe possible interactions between the renin-angiotensin and nitrergic systems in chronic hypoxia-induced pulmonary hypertension in newborn piglets. Thirteen chronically instrumented newborn piglets (6.3 ± 0.9 days; 2369 ± 491 g) were randomly assigned to receive saline (placebo, P) or the AT1 receptor (AT1-R) blocker L-158,809 (L) during 6 days of hypoxia (FiO2 = 0.12). During hypoxia, pulmonary arterial pressure (Ppa; P < 0.0001), pulmonary vascular resistance (PVR; P < 0.02) and the pulmonary to systemic vascular resistance ratio (PVR/SVR; P < 0.05) were significantly attenuated in the L (N = 7) group compared to the P group (N = 6). Western blot analysis of lung proteins showed a significant decrease of endothelial NOS (eNOS) in both P and L animals, and of AT1-R in P animals during hypoxia compared to normoxic animals (C group, N = 5; P < 0.01 for all groups). AT1-R tended to decrease in L animals. Inducible NOS (iNOS) did not differ among P, L, and C animals and iNOS immunohistochemical staining in macrophages was significantly more intense in L than in P animals (P < 0.01). The vascular endothelium showed moderate or strong eNOS and AT1-R staining. Macrophages and pneumocytes showed moderate or strong iNOS and AT1-R staining, but C animals showed weak iNOS and AT1-R staining. Macrophages of L and P animals showed moderate and weak AT2-R staining, respectively, but the endothelium of all groups only showed weak staining. In conclusion, pulmonary hypertension induced by chronic hypoxia in newborn piglets is partially attenuated by AT1-R blockade. We suggest that AT1-R blockade might act through AT2-R and/or Mas receptors and the nitrergic system in the lungs of hypoxemic newborn piglets.


Subject(s)
Animals , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Hypoxia/complications , Antihypertensive Agents/therapeutic use , Hypertension, Pulmonary/drug therapy , Imidazoles/therapeutic use , Nitric Oxide Synthase/drug effects , Tetrazoles/therapeutic use , Animals, Newborn , Chronic Disease , Disease Models, Animal , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/metabolism , Immunohistochemistry , Nitric Oxide Synthase/metabolism , Pulmonary Artery/drug effects , Swine , Vascular Resistance/drug effects
7.
Experimental & Molecular Medicine ; : 510-516, 2011.
Article in English | WPRIM | ID: wpr-7977

ABSTRACT

We have investigated the effect of various forms of phosphodiester cytidine-phosphate-guanosine oligodeoxynucleotides (CpG ODNs) on the production of pro-inflammatory cytokines and related genes in RAW 264.7 macrophages. Treatment with the CpG ODNs increased the expression of tumor necrosis factor alpha (TNF-alpha), IL-6, and inducible nitric oxide synthase but not interleukin-1beta (IL-1beta). We also investigated the effect of CpG ODNs on the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) genes which are known to facilitate cholesterol efflux from macrophages for anti-atherosclerosis. CpG 2006 significantly reduced the levels of ABCG1 mRNA as determined by real-time polymerase chain reaction, whereas ABCA1 mRNA level was not changed. Western blot analysis further confirmed the reduction of ABCG1 protein expression by CpG 2006. In addition, we also determined the protein level of peroxisome proliferator activated receptor gamma (PPARgamma), which is recognized as a transcriptional activator of ABC transporters, was also reduced by CpG 2006. Thus, these results suggest that ABCG1 is specifically down-regulated by CpG 2006 in a PPARgamma-dependent manner in macrophages.


Subject(s)
Animals , Mice , ATP-Binding Cassette Transporters/drug effects , Atherosclerosis/metabolism , Cholesterol/metabolism , Cytokines/drug effects , Gene Expression Regulation , Inflammation/metabolism , Interleukin-1beta/drug effects , Interleukin-6/metabolism , Lipoproteins/drug effects , Macrophages/cytology , Nitric Oxide Synthase/drug effects , Oligodeoxyribonucleotides/pharmacology , PPAR gamma/genetics , Tumor Necrosis Factor-alpha/drug effects
8.
Rev. Inst. Med. Trop. Säo Paulo ; 49(1): 11-16, Jan.-Feb. 2007. graf
Article in English | LILACS | ID: lil-444571

ABSTRACT

Iron is an essential growth element of virtually all microorganisms and its restriction is one of the mechanisms used by macrophages to control microbial multiplication. Paracoccidioides brasiliensis, the agent of paracoccidioidomycosis, an important systemic mycosis in Latin America, is inhibited in its conidia-to-yeast conversion in the absence of iron. We studied the participation of iron in the nitric oxide (NO)-mediated fungicidal mechanism against conidia. Peritoneal murine macrophages activated with 50U/mL of IFN-gamma or treated with 35 æM Deferoxamine (DEX) and infected with P. brasiliensis conidia, were co-cultured and incubated for 96 h in the presence of different concentrations of holotransferrin (HOLO) and FeS0(4). The supernatants were withdrawn in order to assess NO2 production by the Griess method. The monolayers were fixed, stained and observed microscopically. The percentage of the conidia-to-yeast transition was estimated by counting 200 intracellular propagules. IFN-gamma-activated or DEX-treated Mthetas presented marked inhibition of the conidia-to-yeast conversion (19 and 56 percent, respectively) in comparison with non-activated or untreated Mthetas (80 percent). IFN-gamma-activated macrophages produced high NO levels in comparison with the controls. Additionally, when the activated or treated-macrophages were supplemented with iron donors (HOLO or FeSO4), the inhibitory action was reversed, although NO production remained intact. These results suggest that the NO-mediated fungicidal mechanism exerted by IFN-gamma-activated macrophages against P. brasiliensis conidia, is dependent of an iron interaction.


O ferro é elemento essencial para o crescimento de microrganismos e sua limitação é um dos mecanismos usados por macrófagos para controlar a multiplicação microbiana. Paracoccidioides brasiliensis, o agente da paracoccidioidomicose, uma das micoses sistêmicas mais importantes na América Latina, é inibido em sua conversão de conídia-à-levedura na ausência do ferro. Estudamos a participação do ferro no mecanismo fungicida mediado pelo óxido nítrico (NO) na sua interação com as conídias do fungo. Macrófagos peritoneais murinos ativados com 50U/mL de IFN-gama ou tratados com 35 æM Deferoxamina (DEX) e infectados com conídias do P. brasiliensis foram co-cultivados e incubados por 96 h na presença de concentrações diferentes de holotransferrina (HOLO) e FeS0(4). Os sobrenadantes foram retirados a fim de avaliar a produção de NO2 pelo método de Griess. Os macrófagos eram fixados, corados e observados ao microscópio. A porcentagem da transição de conídia-à-levedura foi estimada contando 200 propágulos intracelulares. Os macrófagos ativados com citocina ou tratados com DEX apresentaram inibição marcada da conversão de conídia-à-levedura (19 e 56 por cento, respectivamente) em comparação com macrófagos controle (80 por cento). Os macrófagos ativados com IFN-gama produziram elevação nos níveis de NO em comparação com macrófagos não-tratados ou não-activados. Adicionalmente, quando as monocapas ativadas ou tratadas foram suplementadas com doadores do ferro (HOLO ou FeSO4), a ação inibitória foi revertida embora a produção de NO permanecesse intacto. Estes resultados sugerem que o mecanismo fungicida mediado pelo NO exercido por macrófagos ativados com IFN-gama contra conídias do P. brasiliensis é dependente de uma interação do ferro.


Subject(s)
Animals , Male , Mice , Deferoxamine/pharmacology , Interferon-gamma/pharmacology , Iron/pharmacology , Macrophages, Peritoneal/microbiology , Nitric Oxide Synthase/drug effects , Paracoccidioides/growth & development , Transferrin/pharmacology , Mice, Inbred BALB C , Macrophage Activation/drug effects , Macrophages, Peritoneal/drug effects , Paracoccidioides/drug effects , Paracoccidioides/immunology
9.
Bulletin of High Institute of Public Health. 2007; 37 (2): 415-423
in English | IMEMR | ID: emr-172488

ABSTRACT

Physostigmine [eserine] is the methyl carbamic ester of phenolic trimethyl ammonium compound. It is a powerful inhibitor of acetylcholinesterase enzyme activity and used in some therapeutic preparation. In this work, experiments were carried out in-vivo to study the intraperitoneal [i.p.] infusion of eserine on the activity of nitric oxide synthase [NOS] enzyme, obtained from whole and five different parts of rat brain, namely: basal ganglia, frontal cortex medulla oblongata, pons, and cerebellum. In this work ,two experiments were carried Experiment A: to study the dose dependence of i.p. infusion of eserine on NOS activity. Experiment B: to study the time dependence post-infusion of constant dose of eserine [the dose which caused 50% inhibition of the enzyme activity: 150]. The results showed that the "inhibition of the enzyme occurred in each part studied, and the inhibition increased with increasing the infused dose of eserine, and the time post i.p. infusion, i.e., the inhibition is dose and time dependent. The highest inhibition occurred in the pons and medulla oblongata extracts; these parts are responsible for the reflex centers of cough and vital centers


Subject(s)
Animals, Laboratory , Physostigmine/pharmacology , Nitric Oxide Synthase/drug effects , Rats , Brain
10.
Braz. j. med. biol. res ; 38(6): 959-966, June 2005. ilus, tab
Article in English | LILACS | ID: lil-402665

ABSTRACT

Discrepancy was found between enhanced hypotension and attenuated relaxation of conduit arteries in response to acetylcholine (ACh) and bradykinin (BK) in nitric oxide (NO)-deficient hypertension. The question is whether a similar phenomenon occurs in spontaneously hypertensive rats (SHR) with a different pathogenesis. Wistar rats, SHR, and SHR treated with NO donors [molsidomine (50 mg/kg) or pentaerythritol tetranitrate (100 mg/kg), twice a day, by gavage] were studied. After 6 weeks of treatment systolic blood pressure (BP) was increased significantly in experimental groups. Under anesthesia, the carotid artery was cannulated for BP recording and the jugular vein for drug administration. The iliac artery was used for in vitro studies and determination of geometry. Compared to control, SHR showed a significantly enhanced (P < 0.01) hypotensive response to ACh (1 and 10 æg, 87.9 ± 6.9 and 108.1 ± 5.1 vs 35.9 ± 4.7 and 64.0 ± 3.3 mmHg), and BK (100 æg, 106.7 ± 8.3 vs 53.3 ± 5.2 mmHg). SHR receiving NO donors yielded similar results. In contrast, maximum relaxation of the iliac artery in response to ACh was attenuated in SHR (12.1 ± 3.6 vs 74.2 ± 8.6 percent in controls, P < 0.01). Iliac artery inner diameter also increased (680 ± 46 vs 828 ± 28 æm in controls, P < 0.01). Wall thickness, wall cross-section area, wall thickness/inner diameter ratio increased significantly (P < 0.01). No differences were found in this respect among SHR and SHR treated with NO donors. These findings demonstrated enhanced hypotension and attenuated relaxation of the conduit artery in response to NO activators in SHR and in SHR treated with NO donors, a response similar to that found in NO-deficient hypertension.


Subject(s)
Animals , Male , Rats , Acetylcholine/pharmacology , Bradykinin/pharmacology , Hypotension/metabolism , Iliac Artery/drug effects , Nitric Oxide Donors/pharmacology , Vasodilator Agents/pharmacology , Blood Pressure/drug effects , Carotid Arteries/drug effects , Carotid Arteries/physiology , Hypotension/chemically induced , Iliac Artery/pathology , Iliac Artery/physiology , Molsidomine/pharmacology , Nitric Oxide Synthase/drug effects , Pentaerythritol Tetranitrate/pharmacology , Rats, Inbred SHR , Rats, Wistar
11.
Medical Journal of Cairo University [The]. 2005; 73 (4): 839-849
in English | IMEMR | ID: emr-73414

ABSTRACT

Arterial vasodilatation and activation of several vasoactive and neurohumoral systems may play a key role in the pathogenesis of sodium and water retention and ascites formation in cirrhosis. Strong evidence supports a role for an increased vascular production of the potent vasodilator, nitric oxide [NO], in vascular hyporeactivity of cirrhosis. Also, evidence indicated that dihydropyridine-type calcium channel blockers [DHP-CCBs] modulate the release and /or bioavailability of endothelial NO. So, it is possible that DHP-CCBs have the potential to exaggerate the hemodynamic derangements in cirrhosis. The present study was motivated to test the effect of DHP-CCBs [nifidipine] on experimental liver cirrhosis, induced in animal model by using CCI[4], either alone or in the presence of NO synthase inhibitor, N-nitro-L-arginine methyl ester [L-NAME]. Sixty four adult male albino rats were assigned into two main groups, non-cirrhotic [GI], n=32 and cirrhotic [GIl], n=32. Further classification into four subgroups was carried out for each group. GI included: Gla [non treated control], GIb [L-NAME treated], GIc [nifedipine treated] and GId [nifedipine + L-NAME treated]. While GIl included: Glla [cirrhotic untreated], GlIb [cirrhotic, L-NAME treated], GIIc [cirrhotic, nifedipine treated] and GIld [cirrhotic, nifedipine + L-NAME treated]. L-NAME and /or nifedipine administration [according to the group] was orally administrated daily for a week at a dose = 0.5mg/Kg/day for L-NAME and /or = 0.1mg/Kg/day for nifedipine. Results revealed that L-NAME treatment of healthy rats [GIb] had no significant effect on all the tested parameters including B.Wt. and plasma Na, aldosterone and NO levels. Significant elevation in plasma aldosterone and NO mean values was noted by nifedipine administration to non cirrhotic animals [GIc] compared to Gla, however, no significant difference was obtanied between GIc and Gla for each of B.Wt and plasma Na. Results also demonstrated that CCI[4] administration to rats [Glla] resulted in the appearance of ascites with a significant elevation in plasma aldosterone and NO mean values compared to Gla. Treatment of cirrhotic rats with L-NAME had nearly normalized the later two parameters with no significant difference when compared to Gla, beside reduction in ascitic fluid volume and consequently B.Wt. compared to non-treated cirrhotic group [Glla]. Our results indicated that nifedipine administration to cirrhotic rats [GIIc] significantly intensified the abnormalities associated with CCI[4] administration and resisted the normalization by L-NAME treatment [GIld]. It could be concluded that normalization of plasma NO by NO synthase inhibition is associated with improvement in renal sodium and water excretion which in turn resulted in decreased ascitic fluid volume in cirrhotic rats, while DHP-CCBs [nifedipine] by increasing the plasma NO levels exaggerate ascites in cirrhotic rats. This finding may raise the possibility of using long term NO synthase inhibition in patients with ascites and avoidance of the use of calcium channel blockers in those patients


Subject(s)
Animals, Laboratory , Ascites , Nitric Oxide Synthase/drug effects , Nifedipine/adverse effects , Drug Combinations , Carbon Tetrachloride , Kidney Function Tests , Nitric Oxide Synthase/antagonists & inhibitors
12.
Braz. j. med. biol. res ; 34(2): 221-226, Feb. 2001.
Article in English | LILACS | ID: lil-281599

ABSTRACT

Actin-based motor protein requirements and nitric oxide (NO) production are important features of macrophage activity during phagocytosis or microbicidal processes. Different classes of myosins contribute directly or indirectly to phagocytosis by providing mechanical force for phagosome closure or organelle movement. Recent data have shown the presence of myosins IC, II, V and IXb in phagosomes of bone marrow-derived murine macrophages. In our investigation we demonstrated the presence of different classes of myosins in J774 macrophages. We also analyzed the effect of gamma interferon (IFN-gamma), with or without calcium ionophore or cytochalasin B, on myosins as well as on inducible nitric oxide synthase (iNOS) expression and NO production. Myosins IC, II, Va, VI and IXb were identified in J774 macrophages. There was an increase of myosin V expression in IFN-gamma-treated cells. iNOS expression was increased by IFN-gamma treatment, while calcium ionophore and cytochalasin B had a negative influence on both myosin and iNOS expression, which was decreased. The increases in NO synthesis were reflected by increased iNOS expression. Macrophages activated by IFN-gamma released significant amounts of NO when compared to control groups. In contrast, NO production by calcium ionophore- and cytochalasin B-treated cells was similar to that of control cells. These results suggest that IFN-gamma is involved in macrophage activation by stimulating protein production to permit both phagocytosis and microbicidal activity


Subject(s)
Animals , Mice , Cells, Cultured , Interferon-gamma/pharmacology , Macrophages/drug effects , Nerve Tissue Proteins/drug effects , Nitric Oxide Synthase/drug effects , Nitric Oxide/metabolism , Phagocytosis/drug effects , Blotting, Western , Case-Control Studies , Cell Movement/drug effects , Cytochalasin B , Ionophores , Myosins/drug effects
13.
Acta physiol. pharmacol. ther. latinoam ; 46(1): 23-32, 1996. tab, graf
Article in English | LILACS | ID: lil-168103

ABSTRACT

In this paper we analyse the interaction of IgG from T. cruzi infected patients with cardiac muscarinic acetycholine receptors (mAChRs). Human chagasic IgG, activating M2 mAChR simulated the agonist actions excerting negative inotropic effect and simulation of nitric oxide synthase (NOS). Inhibitos of phospholipase C, protein Kinase C, calcium/calmodulin, NOS and guanylate cyclase activities prevented the chagasis effects upon contractility and NOS activity.


Subject(s)
Humans , Animals , Male , Rats , Chagas Disease , Myocardial Contraction , Immunoglobulin G/pharmacology , Muscarinic Agonists , Nitric Oxide , Receptors, Muscarinic , Carbachol/blood , Carbachol/pharmacology , Cyclic GMP , Depression, Chemical , Heart Atria/drug effects , Immunoglobulin G/blood , Immunoglobulin G/isolation & purification , Enzyme Inhibitors/pharmacology , Nitric Oxide Synthase/blood , Nitric Oxide Synthase/drug effects , Nitric Oxide Synthase/metabolism , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL